Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche Takes Option To Buy Lonza Plant

by Michael McCoy
September 7, 2009 | A version of this story appeared in Volume 87, Issue 36

Roche has exercised an option to buy Lonza’s cell culture biologic facility in Singapore. The price is $290 million plus milestone payments of $70 million. Roche says the 80,000-L plant will produce bevacizumab, the active ingredient in the cancer drug Avastin. The sale was anticipated by a 2006 deal between Lonza and Genentech, now part of Roche, under which Lonza bought a Genentech plant in Spain and agreed to eventually sell the Singapore plant to Genentech. Lonza plans to open another 80,000-L cell culture plant in Singapore by 2011.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.